

Opioid Use During Pregnancy

- 1** **Opioid use during pregnancy** is directly related to Neonatal Abstinence Syndrome (NAS), a group of conditions caused when babies go through withdrawals from drugs they are exposed to in the womb before birth.
- 2** **A baby exposed to opioids before birth** could experience drug withdrawal after birth.
- 3** **Opioid use can cause** babies to be born with low birthweight, increased rates of growth restriction, breathing and feeding problems, Jaundice, Sepsis, seizures, and impaired parent-infant attachment.
- 4** **Average length of stay** for a newborn with NAS is 16.9 days (without NAS is 2.1 days).
- 5** **Average cost of hospital stay** is \$66,700 (without NAS is \$3,000).
- 6** **Infants exposed to opioids in utero** are more likely to develop acute renal failure and suffer mortality prior to hospital discharge.
- 7** **Substance exposed newborns** are more likely to experience abuse or neglect, adverse neurodevelopmental outcomes and re-hospitalization after birth.

• "Neonatal Abstinence Syndrome (NAS)." March of Dimes, [www.marchofdimes.org/neonatal-abstinence-syndrome-\(nas\).aspx](http://www.marchofdimes.org/neonatal-abstinence-syndrome-(nas).aspx).
• Patrick et. Al., JAMA 2012. Patrick et. Al., Journal of Perinatology 2015
• Stanfordchildrens.org. (2018). default - Stanford Children's Health, <http://www.stanfordchildrens.org/en/topic/default?id=neonatal-abstinence-syndrome-90-P02387>
• Whiteman, V. E., Salemi, J. L., Mogos, M. F., Cain, M. A., Aliyu, M. H., & Salihu, H. M. (2014). Retrieved March 07, 2018, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164310/>
• Patrick SW, Schiff DM, PREVENTION COSUA. A Public Health Response to Opioid Use in Pregnancy. Pediatrics 2017;139; 2. Devlin LA, Lau T, Radmacher PG. Decreasing Total Medication Exposure and Length of Stay While Completing Withdrawal for Neonatal Abstinence Syndrome during the Neonatal Hospital Stay. Front Pediatr 2017;5:216; 3. Raffaelli G, Cavallaro G, Allegaert K, et al. Neonatal Abstinence Syndrome: Update on Diagnostic and Therapeutic Strategies. Pharmacotherapy 2017;37:814-23

